Investigational molecule protects against ALS-linked cellular toxicity
FundaMental Pharma’s investigational molecule FP802 reduced neurological disability, protected nerve cells, and prolonged survival in a…
Articles by Lindsey Shapiro, PhD
C9ORF72 gene mutations drive inflammatory molecule’s production
Mutations in the C9ORF72 gene may lead to amyotrophic lateral sclerosis (ALS) and the related disorder…
Phase 3 trial of oral pridopidine in treating ALS likely this year
On the heels of promising HEALEY-ALS Phase 2 trial data, Prilenia Therapeutics plans to launch a pivotal Phase 3…
Blocking signaling pathways may reverse nerve cell changes in ALS
Blocking certain inflammatory signaling pathways may be one way to reverse nerve cell alterations that drive the symptoms of…
Daily IPL344 for up to 3 years seen to slow ALS progression in trial
Up to three years of daily treatment with the investigational therapy IPL344 was well tolerated and slowed disease progression…
Researchers develop algorithm to predict ALS survival
Researchers have developed an algorithm to generate personalized survival predictions for people with amyotrophic lateral sclerosis (ALS) based on…
ALS Association helping to move ORY-4001 into animal studies
The ALS Association has given Oryzon Genomics nearly $500,000 to advance ORY-4001, a potential treatment of amyotrophic…
ALS/MND 2023: European study spotting factors that affect progression
Genetic and clinical factors that can influence how amyotrophic lateral sclerosis (ALS) progresses were identified in a recent analysis…
ALS/MND 2023: Gout med fails to show efficacy in small trial
Colchicine, an anti-inflammatory medication used to treat gout, was safe, but did not significantly slow the progression of amyotrophic…
ALS/MND 2023: Blood sugar-boosting diet may slow ALS progression
Eating foods with a higher glycemic index — those more likely to quickly raise a person’s blood sugar — is…